ArticleScience translational medicine2024
Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 25 citations in OpenAlex.
- Clostridioides difficile as a Zoonotic and Foodborne Pathogen: Reviewing the Global Evidence and South African Data.MicrobiologyOpen · 2026Review
- The gut microbiome and ageing trajectories: mechanisms and clinical implications.Nature reviews. Endocrinology · 2026Review
- Antibiotic-induced gut microbiome dysbiosis: risks and strategies for mitigation.The EMBO journal · 2026Review
- Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Evolutionary digital twin framework for optimal aminoglycoside dosing in neonates with suspected sepsis.NPJ digital medicine · 2026Article
- Antimicrobial Resistance Along the Food Chain: Spread and Integrated Strategies for Mitigation and Control.Antibiotics (Basel, Switzerland) · 2026Review
- Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.Frontiers in immunology · 2026Review
- Gut microbiota-driven immunomodulation in tuberculosis: targeting dysbiosis to overcome drug resistance.Frontiers in immunology · 2026Review
- Factors influencing gut microbial colonization: A host-microbe-environment interaction perspective.Current research in food science · 2026Review
- The swine IsoLoop model of the gut host-microbiota interface enables intra-animal treatment comparisons to advance 3R principles.Gut microbes · 2025Article
- Microbiome-driven resistance in cervical cancer therapy: from mechanistic dissection to clinical translation.Expert reviews in molecular medicine · 2025Review
- Gut microbiota and tuberculosis infection: interaction and therapeutic potential.Gut microbes · 2025Review
- Smart hybrid nanomaterials for chronic infections: microbiome-responsive and sustainable therapeutic platforms.Journal of nanobiotechnology · 2025Review
- Pre-Colonization of Bacillus siamensis on Ocular Surface Mitigates Fusarium keratitis Through Direct Antifungal Activity and Pre-Activation of NF-κB Pathway.Investigative ophthalmology & visual science · 2025Article
- Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health.Molecular biology reports · 2025Review
- Where lung cancer and tuberculosis intersect: recent advances.Frontiers in immunology · 2025Review
- Utilization of machine learning to predict antibiotic resistant event outcomes in acute myeloid leukemia patients undergoing induction chemotherapy.Frontiers in cellular and infection microbiology · 2025Article
- Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challenges.Frontiers in microbiology · 2025Review
- A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.Signal transduction and targeted therapy · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Shakti K BhattaraiDepartment of Microbiology and Physiological Systems, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0001-9118-9184
Muxue DuImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abigail L ZeamerDepartment of Microbiology and Physiological Systems, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-3600-4519
Benedikt M MorzfeldDepartment of Microbiology and Physiological Systems, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0003-0563-8970
Tasia D KelloggDepartment of Microbiology and Physiological Systems, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0001-6294-0098
Kaya FiratCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.ORCID 0000-0001-8655-2065
Anna BenjaminImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-6159-6440
James M BeanImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-6733-5794
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.ORCID 0000-0002-4390-3555
Gertrude MardiHaitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
Stalz Charles VilbrunHaitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.ORCID 0009-0002-9482-1725
Kathleen F WalshCenter for Global Health, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-9001-3918
Daniel W FitzgeraldCenter for Global Health, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0003-1765-0598
Michael S GlickmanImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7918-5164
Vanni BucciDepartment of Microbiology and Physiological Systems, UMass Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-3257-2922
University of Massachusetts Chan Medical School · USMemorial Sloan Kettering Cancer Center · USCornell University · USGheskio Centers · HTHackensack Meridian Health · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MPharmacology & ImmunoPathology (PIP) CoreU19AI162568 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2021 to 2025
$13.0MChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2MAging Microbiome, Immunosenescence, and risk of Multi-drug Resistant Organism Colonization and Infection in the Nursing HomeR01AG075283 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Vanni Bucci, John Patrick Haran · 2023 to 2026
$2.8MDevelopment of targeted microbiome therapeutics and dietary interventions for potent intestinal barrier promotion to minimize GI-ARSU01AI172987 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Vanni Bucci, Beth A McCormick · 2023 to 2026
$2.3MSentinel populations and transmission hotspots of isoniazid-resistant tuberculosisK23AI175686 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Kathleen F Walsh · 2023 to 2026
$782kNCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NIAID NIH HHS K23 AI175686NIAID NIH HHS U01 AI172987NIAID NIH HHS U19 AI162568NIA NIH HHS R01 AG075283NIGMS NIH HHS R01 GM129325
Abstract
Despite their therapeutic benefits, antibiotics exert collateral damage on the microbiome and promote antimicrobial resistance. However, the mechanisms governing microbiome recovery from antibiotics are poorly understood. Treatment of
Indexed as
Gastrointestinal MicrobiomeMicrobiotaResilience, PsychologicalAnimalsAnti-Bacterial AgentsDrug Resistance, BacterialHumansMiceAnti-Bacterial Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.